Therapeutic agent for disc herniation

Abstract

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.

1 . A therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk. 
     
     
         2 . The therapeutic agent according to  claim 1 , wherein the disc herniation is a lumbar disc herniation. 
     
     
         3 . The therapeutic agent according to  claim 1 , wherein the chondroitinase ABC is derived from Proteus vulgaris. 
     
     
         4 . A formulation containing chondroitinase ABC for treating disc herniation by the administration into a human disk in an amount of 1-8 units per disk. 
     
     
         5 . The formulation according to  claim 4 , wherein the formulation is a single dose formulation. 
     
     
         6 . The formulation according to  claim 4 , wherein the formulation is an injection. 
     
     
         7 . The formulation according to  claim 4 , wherein the disc herniation is a lumbar disc herniation. 
     
     
         8 . A method for treating disc herniation, comprising administering chondroitinase ABC to a human disk of a patient with disc herniation in an effective amount of 1-8 units per disk. 
     
     
         9 . (canceled)